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Phosphatidylinositol4,5-bisphosphate (PIP,) at 0.1 mob% activated the protein kinase C (PKC)-mediated phosphorylation of 87-, 55- and 47-kDa 
brain proteins. Neomycin, an aminoglycoside antibiotic that binds PIP, with a high affinity, inhibited PIP;PKC activity in a concentration-depen- 
dent manner. Low concentrations of neomycin (< 2 mM) did not affect DG.PKC activity; however, 4 mM neomycin inhibited SW of this activity. 
This inhibition of DG-stimulated activity at high neomycin concentration may be the result of its binding to Ca*+ and ATP in the assay system. 
These results suggest hat PIP, is a physiological activator of PKC, and show that neomycin can be an inhibitor of PIP,.PKC activity at concentra- 
tions where DG.PKC activity is not affected. 
Neomycin; Protein kinase C; Phosphatidylinositol4,5bisphosphate 
1. INTRODUCTION 
Neomycin, an ototoxic and nephrotoxic polycationic 
antibiotic, has been shown to interact with anionic 
phospholipids such as the polyphosphoinositides [l-3]. 
It binds phosphatidylinositol 4,5bisphosphate (PIP2) 
preferentially over phosphatidylinositol 4-phosphate 
(PIP) and lacks affinity for phosphatidylinositol (PI) 
[3-51. The strong affinity of neomycin for PIP2 has 
provided the basis for its use in purification of PIP2 [6], 
and it has generated numerous studies of its role in 
signal transduction [7-91. Neomycin appears to dampen 
the intracellular signal [ 10,l l] by inhibiting the phos- 
pholipase C-mediated PIP2 breakdown that leads to the 
formation of inositol 1,4,5_triphosphate (IP$ and 
1,2-diacylglycerol (DG). Both these compounds have 
second messenger function, with IPs causing release of 
intracellular calcium (Ca”) and DG acting syner- 
gistically with Ca2+ to activate protein kinase C, a 
calcium/phosphatidylserine (PS)-dependent protein 
phosphorylating enzyme [ 12,131. Recent evidence from 
this laboratory has demonstrated that PIP2 in the 
presence of Ca2+ and PS can itself act as an activator 
of PKC (Kprpz= 0.04 mol% with histones as a 
substrate) [14],’ and that it is a competitive inhibitor of 
phorbol ester binding (and, by implication, DG bin- 
ding) to PKC [ 151. This report demonstrates that PIP2 
activates the PKC-mediated phosphorylation of its 
specific substrates from rat brain: 87 kDa, 55 kDa and 
47 kDa proteins and that neomycin inhibits PIP2. PKC- 
mediated protein phosphorylation. 
2. MATERIALS AND METHODS 
All reagents were purchased from Sigma. The purity of lipids was 
confirmed by thin layer chromatography. [y-‘*P]ATP was bought 
from NEN. GF/C filters were from Whatman. 
2.1. Purification of protein kinase C 
The enzyme was purified from rat brains by the method of 
Woodgett and Hunter [16] with DE52, phenyl-Sepharose 4B and PS- 
acrylamide column chromatography. The final preparation, a mix- 
ture of (Y-, fl- and yPKC isoenzymes, was concentrated by reverse 
dialysis against solid polyethlene glycol 8000, dialyzed overnight at 
4°C into 20 mM Tris-HCl, pH 7.5, containing 0.1% (v/v) mercap- 
toethanol, 100,uM EGTA, and 10% glycerol, and stored at 4°C. The 
specific activities of DC. PKC and PIP*. PKC were 3 and 1.3 
pmol/mg per min, respectively, at 37°C in a mixed micellar assay [17] 
with Triton X-100,0.3%; PS, 9 mol%; Ca*+, 50,4M; DC, 2 mol% or 
PIP*, 0.1 mol%. 
2.2. Phosphorylation of brain proteins by PIP*. PKC and DC. PKC 
A calmodulin-depleted soluble fraction was prepared from rat 
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cerebral cortex by DEAE-cellulose chromatography [18]. Briefly, 
fresh rat cerebral cortex was homogenized in 1 vol. of ice-cold solu- 
tion A (0.25 M sucrose, 25 mM Tris-HCl, pH 7.5, 10 mM MgClz, 50 
mM mercaptoethanol, 0.3 mM EGTA, and 2 mM phenylmethyl- 
sulfonyl fluoride). After centrifugation of the homogenate at 
105 000x g for 60 min, the supernatant was loaded onto a DEAE- 
cellulose column equilibrated with solution B (20 mM Tris-HCI, pH 
7.5, 50 mM mercaptoethanol) and eluted with 250 mM KC1 dissolved 
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in solution B. The eluate was used as the source of endogenous PKC 
and its substrate proteins. The effect of PIP2 and DC on the 
phospboryIation of c~modulin-deficient cytosolic proteins was com- 
pared under standard PKC assay conditions. Micelles of PS, PS/DG 
and PS/PIP2 were prepared by drying the required amount of lipids 
under a stream of nitrogen in a glass tube followed by soiubilization 
in 3% Triton X-100 by vortexing and incubating for 5 min at 37’C 
[17]. Aliquots of the &ate containing 100 pg protein were phos- 
phorylated by incorporation of “P from [Y-~‘P]ATP in the micellar 
system in presence of 20 mM Tris-HCl, pH 7.5,SOpM Car’, 10 mM 
MgCla, and 50agfmI leupeptin. The reaction was terminated by the 
addition of sodium dodecylsuifate stop solution, i.e. 20% (v/v) 
glycerol/lO% (w/v) sodium dodecylsuffate/lOC (v/v) 2-mercapto- 
ethanol/O.25 M Tris-HCI, pH 6.7, and heating in a boiling water bath 
for 2 min. The proteins were separated by SDS-slab gel electro- 
phoresis (with 5-15% linear gradient polyacrylamide gels) and the 
Iabeliled phosphoproteins were detected by autoradiography. The 
relative intensity of labelled phosphoprot~ns was quantified by 
densitometric tracing of the autoradiogram with a Sbimadzu CS%JOO 
densitometer. 
2.3. Effect of neomycin on PIP2. PKC and DG- PKC activity 
PKC activity was assayed in the absence and presence of neomycin 
(1, 2 and 4 mMf by measuring the incorporation of “P from 
[T-~~P]ATP into histones III in a total reaction voiume of 0. I mi con- 
taining 20 mM Tris-HCl, pR 7.5, 50 PM Ca’*, IO mM MgCla, 0.8 
mg/ml histone IDS, 50 &g/ml leupeptin, 12.5 PM ATP, 10 ~1 lipid 
micelles (PS, PWDG or PS/PIPr) and 10 pl PKC (0.1-0.2 pg). The 
reaction was terminated by adding 1 ml of ice-cold 25% trichloro- 
acetic acid (WA), followed by addition of 1 ml of ice-cold bovine 
serum albumin (400 pg/ml). The resulting precipitate was washed 
four times with ice-cold TCA, collected on a 2.5 cm GF/C filter, and 
counted in IO mt of hydroffuor. The effect of neomycin on the 
phospho~ylatjon of c~modulin-de~c~ent soluble cortex proteins was 
measured in the same manner. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the effect of DG and PIP2 on protein 
phosphorylation in the ~~modulin~d~pleted soluble 
fraction of rat brain cerebral cortex. PIP2 (0.1 mol%) 
stimulated the phospharylation of the 87 kDa and 47 
kDa (known PKC-substrate proteins) significantly. If 
DG (2 mol%) was the activator, the p~osphorylation 
for these proteins was stimulated 2-fold greater than it 
was with PIP2 (0.1 moWo). These results are in accord 
with the previous observation [14] that PKC is activated 
more efficiently by PIP2 (KPIPP =0.04 mol% in 
Triton/lipid micelles with histones as substrate) than by 
DC (lcr, = 2 mol%) although the maximal velocity of 
phospho~lation is 2-3 times greater with DG-PKC 
than with PIP2 - PKC. The role of PKC-mediated 
phospharylation of the 87 kDa protein in neurotrans- 








Fig. 1, Autoradiographs howing the stimulation of phosphorylation of 87-, 55- and 47-kDa brain proteins by PIP2. PKC and DO - PKC (Fig la). 
The calmodulin-depleted soluble fraction of rat cerebral cortex was prepared by DE&P-cellulose column chromatography US]. A mixed micellar 
assay system was used. The additions were: (lane 1) 4 mM EGTA (No Cazf); (lane 2) Ca*+; (lane 3) CaZC + PS; (lane 4) Ca’” + PS + DC; (lane 
5) CaZ* + PS + PIPI. The final concentrations in the reaction mixture were: Ca 2+ 50,&l; PS 9 mol% or 445pM; DG 2 molOls or 99pM; and PtPz 
0.1 moi% or 4.95 FM. Pig, lb represents densitometric scans of the above autoradiogram. Pane& A, B and C represent lanes 3,4 and 5, i.e. addi- 
tions were. (A) Ca” + PS; (B) Ca2’ + PS + Do, and (C) Car+ + PS f PIPz. 
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Fig. 2. Effect of neomycin on phosphorylation of histones by 
PIP2. PKC and DG . PKC. Neomycin was solubilized in 20 mM Tris- 
HCl, containing 0.1% mercaptoethanol, and the pH was adjusted to 
7.5. The phosphorylation of histones III-S was measured with PS, 
PS/PIP2 and PS/DG micelles, as described under section 2. The con- 
centrations of lipids enpressed as mol% of TritonX-100 were: PS 9 
mol% or 445 a; PIP2 0.1 mol% or 4.95 PM; and DG 2 mol% or 99 
pM. PIP2. PKC or DC. PKC activities were calculated by subtracting 
the activity obtained for PS/Ca2+ from that obtained for 
PIPz/PS/Ca’+ or DG/PS/Ca2+ in the absence and presence of 
neomycin. ‘Percent inhibition’ refers to the inhibition of that portion 
of PKC activity obtained by stimulation with PIP2 (0) or DG (0). 
Each point represents the mean + SE of 3 different experiments. 
documented [19,20]. The 47 kDa protein has been sug- 
gested to be related to GAP-43/pp 46/B-50/protein Fl , 
a phosphoprotein implicated in neural and behavioral 
plasticity of hippocampal long-term potentiation, i.e. 
memory [21-231. The phosphorylation of the 55 kDa 
protein was also stimulated by both DG and PIP2. 
Although the identity of the 55 kDa protein is not 
known, it is possible that it may be related to the 
microtubule-associated protein tau, which is known to 
be a substrate for PKC [24]. The tau protein, a family 
of 4-5 closely related phosphoproteins of 45-62 kDa, 
plays a multiple role in interaction and regulation of 
cytoskeletal components. 
Since neomycin specifically binds to PIP2 [3-51, the 
effect of neomycin on PIPs-stimulated PKC activity 
was investigated. Neomycin inhibited PIP2 . PKC ac- 
tivity in a dose-dependent manner in the experiments 
with histones (Fig. 2) or the calmodulin-depleted solu- 
ble fraction of rat cerebral cortex (Fig. 3) as a substrate. 
Low concentrations of neomycin ( < 2 mM) did not af- 
fect DG. PKC activity, but at a 4 mM concentration 
neomycin could inhibit this activity by 50%. The inhibi- 
tion of DG-stimulated PKC activity at a high concen- 
tration of neomycin may be the result of its interaction 
with Ca2+ [25] and ATP [26], which are essential cofac- 
tors for PKC-mediated protein phosphorylation reac- 
tions. These results suggest hat neomycin can be an in- 
hibitor of PIP2 . PKC activity, in addition to its other 
effects on signal transduction, e.g. inhibition of phos- 
pholipase C-mediated PIP2 breakdown [ 10,111, IPJ- 
induced Ca2+ release [26], Ca2+-dependent histamine 
secretion from GTP-ys-loaded mast cells [27], and 
thrombin-stimulated initiation of cell-proliferation 
WI. 
Neomycin (mM) 
Fig. 3. Effect of neomycin on PIPz.PKC- and DG.PKC-mediated 
phosphorylation of calmodulin-depleted soluble proteins from rat 
cerebral cortex. The calmodulin-deficient cytosol was prepared from 
rat cerebral cortex by DEAE-cellulose chromatography, and used as 
a source of PKC and its substrate proteins. Other experimental condi- 
tions were the same as described under Fig. 2, with the omission of 
histone. 
Since PIP2 is an activator of PKC, then room must be 
made for its new function in the present schemes of in- 
ositol lipid cascades. The role of DG, which is generally 
assumed to be the only receptor-linked PKC activator, 
will have to be reevaluated. The conventional role of 
phosphoinositides as the sole source of agonist-induced 
DG has been challenged by recent reports [29] that 
stimulus-responsive DG originates mainly from 
phosphatidylcholine (PC) by the action of PC-specific 
phospholipase C [30,31] or by a phospholipase- 
D/phosphatidase-phosphatase pathway [32]. PIP2 is a 
normal component of the plasma membrane, with a 
concentration between 0.1-I mol% of total lipid. The 
activation of PKC may start with a rise of intracellular 
Ca2+ (of as yet unknown origin) to a threshold Ca2+ 
level and the subsequent formation of a ternary, active 
Ca . PIP2 . PKC complex. Further control could be fur- 
nished by the inositide shuttle, i.e. the phosphorylation 
and dephosphorylation of the inositides, since phos- 
phatidylinositol (PI) does not activate PKC [ 141 or bind 
to it (unpublished), and phosphatidylinositol 4-phos- 
phate (PIP) is a very weak activator [14], and it trans- 
locates the enzyme from cytosol to membrane, and also 
binds to its activator-receiving region weaker than PIP2 
(unpublished observations). DG might act as a secon- 
dary effector of PKC, or may complement PIP2 in the 
stimulation of the enzyme during prolonged activation 
of PKC. 
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